Navigation Links
Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer

For patients with high-risk breast cancer treated with radical mastectomy and adjuvant chemotherapy, the addition of radiation therapy leads to better survival outcomes with few long-term toxic effects, according to a 20-year follow-up of a randomized trial, which appears in the January 19 issue of the Journal of the National Cancer Institute.

The British Columbia randomized radiation therapy trial was designed to determine the effect on survival of the addition of locoregional radiation therapy (radiation to the lymph nodes and chest wall) to a course of chemotherapy after radical mastectomy in premenopausal women with lymph node–positive breast cancer. Between 1979 and 1986, 318 patients were randomly assigned to receive no radiation therapy or to receive radiation. A 15-year follow-up found that radiation therapy was associated with improved breast cancer survival but not with overall survival.

In this 20-year follow-up of the British Columbia trial, Joseph Ragaz, M.D., of McGill University Health Center in Montreal, and colleagues found that the chemotherapy and radiation regimen, compared with chemotherapy alone, was associated with improvement in all end points analyzed. This included a 32% reduction in breast cancer mortality and a 27% reduction in overall mortality compared with chemotherapy alone. In addition, long-term toxic effects, including cardiac deaths, were acceptable for both groups of patients.

"Our results, and those from other groups, confirm that in situations where residual disease remains, adjuvant chemotherapy alone in high-risk breast cancer patients is suboptimal and that the addition of locoregional radiation therapy is important to achieve the highest cure rate," the authors write.

In an editorial, Timothy Whelan, B.M., B.Ch., and Mark Levine, M.D., of the Juravinski Cancer Centre in Hamilton, Ontario, discuss the use of locoregional radiation therapy in breast cancer patients and note that fewer clinicians accept its use in moderate-risk patients. "Because uncertainties continue about the effectiveness of locoregional radiation therapy after mastectomy in moderate-risk patients, we strongly urge that a randomized controlled trial be mounted to resolve these uncertainties," they write.


'"/>

Source:Journal of the National Cancer Institute


Related biology news :

1. Adding radiation decreases breast cancer recurrence
2. Duke Experiments Boost Radiations Cancer-Killing Effects
3. Radiation-killed bacteria vaccine induces broad immune response in mice
4. Radiation-armed robot rapidly destroys human lung tumors
5. Radiation after surgery doubles survival time for some lung cancer patients
6. Radiation therapy combo cures prostate cancer long-term
7. Novel Therapy Tested in Mice Could Chase Away Cat Allergies
8. Gene Therapy For Parkinsons Disease Moves Forward In Animals
9. Rush Physicians Using Gene Therapy For Heart Patients With Moderate To Severe Chest Pains Who Do Not Benefit From Other Treatments
10. Pathogen-Mimicking Vaccine As Strategy For Cancer Therapy
11. Discovery Promises Simpler Therapy for Sickle Cell Disease
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/14/2018)... ... 2018 , ... uBiome, the leader in microbial genomics, announced ... and Therapeutics” by the US Patent and Trademark Office on July 11, 2017 ... by uBiome collaborators Dr. Zachary Apte, Dr. Daniel Almonacid, Dr. Jessica Richman, and ...
(Date:12/13/2018)... ... December 12, 2018 , ... Illumina, Kaiser Permanente, ResMed and Aetna ... The San Diego-based team-building and cooking events company has hosted an impressive guest list ... challenges. , Each group who visits receives a completely customized experience, right ...
(Date:12/10/2018)... ... December 10, 2018 , ... Today, RoosterBio Inc. ... shared goal of accelerating the development of the Regenerative Medicine field. This ... core technology around human umbilical cord perivascular cells (HUCPVCs). Together, it is ...
Breaking Biology News(10 mins):
(Date:1/10/2019)... ... January 08, 2019 , ... ... announced today that SAGICO will be represented at the 37th Annual J.P. ... Healthcare Conference is the largest and most informative healthcare investment symposium in ...
(Date:1/4/2019)... N.C. (PRWEB) , ... January 04, 2019 , ... ... is pleased to welcome Ted Hoffman to the firm. Ted will be joining ... of experience working in and providing consulting services to the pharmaceutical industry. At ...
(Date:12/19/2018)... ... December 19, 2018 , ... R3 Stem Cell is now ... Course in Las Vegas. Training includes facial rejuvenation, hair restoration and erectile dysfunction ... for aesthetics, having the training from expert, Board Certified providers is critical to ...
(Date:12/14/2018)... ... December 14, 2018 , ... NOVA OCULUS ... given the green light to immediately begin a clinical patient trial in Edmonton ... devices bureau of Health Canada has granted what is called an Investigational Testing ...
Breaking Biology Technology: